
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $600.0 million
Deal Type : Collaboration
Flagship Pioneering and Metaphore Biotechnologies Collaborate with Novo on Obesity
Details : Under the collaboration, Novo will leverage Metaphore's MIMICTM platform in the discovery and development of two multitarget therapeutics leveraging GLP-1R and related biology for obesity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 09, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $600.0 million
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : Flagship Pioneering
Deal Size : $50.0 million
Deal Type : Financing
Details : The proceeds will advance Metaphore's MIMiC drug discovery platform and build its pipeline for autoimmune, metabolic or oncology indications. The MIMiC™ platform drives unprecedented insights into molecular interactions to design new biomolecules for t...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 16, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : Flagship Pioneering
Deal Size : $50.0 million
Deal Type : Financing
